Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptinyx Inc (NQ: APTX )

0.1899 +0.0115 (+6.45%)
Streaming Delayed Price Updated: 9:33 AM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptinyx Inc

< Previous 1 2 Next >
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update
From Aptinyx Inc.
Via Business Wire
Aptinyx to Present at the SVB Securities Global Biopharma Conference
From Aptinyx Inc.
Via Business Wire
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
From Aptinyx Inc.
Via Business Wire
Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant
From Aptinyx Inc.
Via Business Wire
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
From Aptinyx Inc.
Via Business Wire
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
From Aptinyx Inc.
Via Business Wire
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting
From Aptinyx Inc.
Via Business Wire
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
From Aptinyx Inc.
Via Business Wire
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
From Aptinyx Inc.
Via Business Wire
Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs
From Aptinyx Inc.
Via Business Wire
Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx Announces Formation of Scientific Advisory Board
From Aptinyx Inc.
Via Business Wire
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022
From Aptinyx Inc.
Via Business Wire
Aptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress Disorder
From Aptinyx Inc.
Via Business Wire
Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
From Aptinyx Inc.
Via Business Wire
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
From Aptinyx Inc.
Via Business Wire
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
From Aptinyx Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.